A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study
Moderna and Merck's personalized mRNA vaccine intismeran cut the risk of melanoma returning by 42 per cent two years after surgery, in a study of more than 1,100 people with high-risk melanoma. Two years on, 82 per cent of vaccinated patients were recurrence-free, versus 70 per cent on Keytruda alone. The companies are discussing approval with regulators; full results were due at a European oncology meeting in Madrid.
A personalized mRNA vaccine, matched to each patient's tumour, is moving toward approval after a large trial showed a clear gain in living without recurrence.
Full results presented at ESMO meeting, Madrid: Oct 24, 2026 All deadlines
Read the original
News source: A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study (opens in a new tab) — CBC News
This summary was written by AI from the source’s published text and was not checked by a person before publication. If it disagrees with the source, the source is right.